http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Raykov+Rosty/26591575.html si-local-file:///var/storage/secattach/20260602/26591575.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Raykov+Rosty/26591575.html Tue, 02 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Raykov+Rosty/26591575.html si-local-file:///var/storage/secattach/20260602/26591575.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Raykov+Rosty/26591575.html Tue, 02 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++144++++++++FENNEC+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+Raykov+Rosty/26583778.html si-local-file:///var/storage/secattach/20260601/26583778.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++FENNEC+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+Raykov+Rosty/26583778.html Mon, 01 Jun 2026 16:14:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++144++++++++FENNEC+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+Raykov+Rosty/26583778.html si-local-file:///var/storage/secattach/20260601/26583778.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++FENNEC+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+Raykov+Rosty/26583778.html Mon, 01 Jun 2026 16:14:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Cioffi+Christiana+Marie/26583545.html si-local-file:///var/storage/secattach/20260601/26583545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Cioffi+Christiana+Marie/26583545.html Mon, 01 Jun 2026 16:07:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Cioffi+Christiana+Marie/26583545.html si-local-file:///var/storage/secattach/20260601/26583545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Cioffi+Christiana+Marie/26583545.html Mon, 01 Jun 2026 16:07:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Andrade+Robert/26583486.html si-local-file:///var/storage/secattach/20260601/26583486.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Andrade+Robert/26583486.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Andrade+Robert/26583486.html si-local-file:///var/storage/secattach/20260601/26583486.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Andrade+Robert/26583486.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Sayad+Pierre+Sargis/26583490.html si-local-file:///var/storage/secattach/20260601/26583490.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Sayad+Pierre+Sargis/26583490.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Sayad+Pierre+Sargis/26583490.html si-local-file:///var/storage/secattach/20260601/26583490.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Sayad+Pierre+Sargis/26583490.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Evans+Terry+L/26583498.html si-local-file:///var/storage/secattach/20260601/26583498.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Evans+Terry+L/26583498.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Evans+Terry+L/26583498.html si-local-file:///var/storage/secattach/20260601/26583498.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Evans+Terry+L/26583498.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Hackman+Jeffrey+S./26583501.html si-local-file:///var/storage/secattach/20260601/26583501.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Hackman+Jeffrey+S./26583501.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Hackman+Jeffrey+S./26583501.html si-local-file:///var/storage/secattach/20260601/26583501.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+31++Filed+by%3A+Hackman+Jeffrey+S./26583501.html Mon, 01 Jun 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+21/26541518.html si-local-file:///var/storage/secattach/20260522/26541518.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+21/26541518.html Fri, 22 May 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+21/26541518.html si-local-file:///var/storage/secattach/20260522/26541518.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++FENNEC+PHARMACEUTICALS++++For%3A+May+21/26541518.html Fri, 22 May 2026 16:06:00 -0400 FENC O.21047090 http://www.streetinsider.com/Analyst+PT+Change/+Fennec+Pharmaceuticals+Inc.+%28FENC%29+PT+Raised+to+%2416+at+H.C.+Wainwright/26538365.html (Updated - May 22, 2026 6:51 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Fennec Pharmaceuticals Inc. (NASDAQ: FENC) to $16.00 (from $13.00) while maintaining a Buy rating.</p><p>The analyst commented: "We draw investors' attention to the fact that adoption continues to build across both new and existing accounts, with established prescribers demonstrating growing confidence in PEDMARK (sodium thiosulfate), contributing to deeper utilization and higher vials per account. Demand in 1Q26 was driven by prescribing in three core tumor types: testicular, cervical and head and neck cancers. Through ongoing operational refinements, more patients are entering the funnel, while http://www.streetinsider.com/Analyst+PT+Change/+Fennec+Pharmaceuticals+Inc.+%28FENC%29+PT+Raised+to+%2416+at+H.C.+Wainwright/26538365.html Fri, 22 May 2026 06:51:31 -0400 FENC http://www.streetinsider.com/Analyst+Comments/+Fennec+Pharmaceuticals+Inc.+%28FENC%29+PT+Raised+to+%2416+at+H.C.+Wainwright/26538365.html (Updated - May 22, 2026 6:51 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Fennec Pharmaceuticals Inc. (NASDAQ: FENC) to $16.00 (from $13.00) while maintaining a Buy rating.</p><p>The analyst commented: "We draw investors' attention to the fact that adoption continues to build across both new and existing accounts, with established prescribers demonstrating growing confidence in PEDMARK (sodium thiosulfate), contributing to deeper utilization and higher vials per account. Demand in 1Q26 was driven by prescribing in three core tumor types: testicular, cervical and head and neck cancers. Through ongoing operational refinements, more patients are entering the funnel, while http://www.streetinsider.com/Analyst+Comments/+Fennec+Pharmaceuticals+Inc.+%28FENC%29+PT+Raised+to+%2416+at+H.C.+Wainwright/26538365.html Fri, 22 May 2026 06:51:31 -0400 FENC http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337 http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html <p align="center"><em>~</em><em> Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK</em><em>®</em><em> (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations </em><em>~</em></p> <p align="center"><em>~ </em><em>Real-World Evidence Shows Administration of PEDMARK</em><em>®</em><em> Approximately Six Hours After Cisplatin Can Be Safe &amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity </em><em>~</em></p> <p align="justify">RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html Thu, 21 May 2026 18:01:00 -0400 A.06822034 A.17568519 A.50200982 A.50208664 A.50214646 A.50216726 A.60012004 FENC FRX O.00081842 O.00474218 O.00786879 O.01304637 O.20026344 O.21047090 O.21157671 O.21612337